Brief: Algernon Pharmaceuticals Provides Update On Timing Of Topline Results For Phase 2b/3 Covid-19 Trial Of Ifenprodil
11/03/2021 12:55
March 11 (Reuters) - Algernon Pharmaceuticals Inc AGN.CD :
* ALGERNON PHARMACEUTICALS PROVIDES UPDATE ON TIMING OF
TOPLINE
RESULTS FOR PHASE 2B/3 COVID-19 TRIAL OF IFENPRODIL
* ALGERNON PHARMACEUTICALS - EXPECTS TO REPORT TOPLINE
RESULTS FOR
PHASE 2B PART OF PHASE 2B/3 COVID-19 TRIAL OF IFENPRODIL, IN
LAST WEEK OF MARCH 2021
Source text for Eikon: ID:nGNX6QtJ5j
Further company coverage: AGN.CD
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Grey Matters Health
See all newsBrief: Grey Matters Announces The Closing Of Its Equity And Convertible Debenture Private Placement Totalling CAD $1.12 Million
Brief: Algernon Announces Additional Increase To Private Placement Financing
Brief: Algernon Health Announces Private Placement
Brief: Algernon Announces Closing Of The Private Placement Financing
Brief: Algernon Announces $1 Mln Private Placement